Key facts
- Provigate’s last known valuation is $39.2M.
- It has raised $21.2M; the latest was Later Stage VC ($5.5M) in Oct 2024.
- Notable investors include ANRI, Coral Capital, The University of Tokyo Edge Capital, Ain Holdings, Biojent — 12 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 12 names
- ·Watchlist + deal alerts for Provigate
- ·The full record, as it builds
Funding rounds
No funding rounds for Provigate are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Provigate
Developer of a diagnostic instrument designed to measure the blood sugar of patients. The company's instrument measures parameters of sugar levels with perception-broadening sensors, enabling diabetic patient to regularly monitor their blood glucose levels as part of managing their lifestyle habits.
- Sector
- Healthcare
- HQ
- Tokyo, Japan
- Founded
- 2015
- Employees
- 30
- Website
- provigate.com/
- Ownership
- Privately Held (backing)
Provigate doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Provigate shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Provigate in its N-PORT filings yet. We sweep new filings monthly.